Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANTENGENE-B

3.170
+0.35012.41%
Volume:4.88M
Turnover:15.23M
Market Cap:2.15B
PE:-3.13
High:3.240
Open:2.870
Low:2.870
Close:2.820
Loading ...

Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%

MT Newswires Live
·
Yesterday

BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio

Reuters
·
Yesterday

Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio

THOMSON REUTERS
·
Yesterday

BRIEF-Antengene Corp To Establish Dedicated Artificial Intelligence Department

Reuters
·
19 Feb

Antengene to Establish AI Department

MT Newswires Live
·
19 Feb

Antengene Corp - Plans to Establish a Dedicated Artificial Intelligence Department

THOMSON REUTERS
·
19 Feb

Antengene Corp - Initiative Includes on-Site Deployment of Deepseek

THOMSON REUTERS
·
19 Feb

Antengene Gets Reimbursement Nod for Multiple Myeloma Drug in Taiwan

MT Newswires Live
·
13 Feb

Antengene Announces Xpovio® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients With R/R Mm in the Region

THOMSON REUTERS
·
13 Feb

Antengene Corp - Approval of Xpovio for Public Health Insurance Coverage in Taiwan

THOMSON REUTERS
·
13 Feb

Antengene Presents Results From Two Late-Stage Clinical Studies of Selinexor at Ash 2024

THOMSON REUTERS
·
10 Dec 2024

Antengene Corp - Xpovio's Indication in Dlbcl Included in 2024 China National Reimbursement Drug List

THOMSON REUTERS
·
28 Nov 2024

Antengene Announces Xpovio® (Selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients With Mm in the Country

THOMSON REUTERS
·
18 Oct 2024

BRIEF-Antengene Corp Announces Approval Of SNDA By South Korean Ministry Of Food And Drug Safety

Reuters
·
18 Oct 2024

Antengene's Multiple Myeloma Combination Treatment Gets Supplementary NDA in South Korea

MT Newswires Live
·
18 Oct 2024

Antengene Corp - Approval of Snda by South Korean Ministry of Food and Drug Safety for Xpovio® for Its Third Indication

THOMSON REUTERS
·
18 Oct 2024